Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
NCT: NCT06790784 · RECRUITING
Brief Summary
This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.
Frequently Asked Questions
What is Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR?
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR is a clinical trial registered under NCT06790784. Current status: RECRUITING.
What is the status of NCT06790784?
The current status of NCT06790784 (Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR) is: RECRUITING.
When did Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR start?
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR started on 2025-08-04.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.